Chronic diabetic foot wounds are a leading cause of amputation, morbidity, and hospitalization for patients with diabetes. Negative-pressure wound therapy (NPWT) can putatively facilitate wound healing, but the underlying mechanisms remain unclear. Cellular fibronectin (cFN) and transforming growth factor-β1 (TGF-β1) play an important role in wound healing. This prospective randomized controlled trial evaluated the effects of NPWT on the production of cFN and the expression of TGF-β1 in diabetic foot wounds of patients.
Methods:
From January 2012 to January 2015, 40 patients with diabetic foot wounds were randomly and equally apportioned to receive either NPWT or advanced moist wound therapy (control) for 7 days. Granulation tissue was harvested before and after treatment. Immunohistochemistry and Western blot were performed to evaluate protein levels of cFN and TGF-β1, and real-time polymerase chain reaction (PCR) to measure corresponding mRNA expressions.
Results:
NPWT facilitated the expression of cFN and TGF-β1 in diabetic foot wounds. Immunohistochemical analysis revealed higher levels of cFN and TGF-β1 in the NPWT group than in the control group. Western blot and real-time PCR analysis further showed that protein and mRNA levels of cFN or TGF-β1 were higher in the NPWT group than that in the control group (P < .01, both).
Conclusion:
Our results showed that NPWT facilitated the production of cFN and the expression of TGF-β1 in granulation tissue in diabetic foot ulcers.
AlaviASibbaldRGMayerD. Diabetic foot ulcers: Part I. Pathophysiology and prevention. J Am Acad Dermatol. 2014;70(1):1.e1-1.e18; quiz 19-20.
2.
ArmstrongDGLaveryLA, Diabetic Foot Study Consortium. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet. 2005;366(9498):1704-1710.
3.
ArslanEOzturkOGAksoyAPolatG.Vacuum-assisted closure therapy leads to an increase in plasma fibronectin level. Int Wound J. 2011;8(3):224-228.
4.
BlumePAWaltersJPayneWAyalaJLantisJ.Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes Care. 2008;31(4):631-636.
5.
BrownriggJRGriffinMHughesCO. Influence of foot ulceration on cause-specific mortality in patients with diabetes mellitus. J Vasc Surg. 2014;60(4):982-986.
6.
BrownriggJRDaveyJHoltPJ. The association of ulceration of the foot with cardiovascular and all-cause mortality in patients with diabetes: a meta-analysis. Diabetologia. 2012;55(11):2906-2912.
7.
DaiglePDespatisMAGrenierG.How mechanical deformations contribute to the effectiveness of negative-pressure wound therapy. Wound Repair Regen. 2013;21(4):498-502.
8.
Demidova-RiceTNHamblinMRHermanIM.Acute and impaired wound healing: pathophysiology and current methods for drug delivery, part 2: role of growth factors in normal and pathological wound healing: therapeutic potential and methods of delivery. Adv Skin Wound Care. 2012;25(8):349-370.
9.
DumvilleJCHinchliffeRJCullumN. Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus. Cochrane Database Syst Rev. 2013;10:CD010318.
10.
FalangaV.Wound healing and its impairment in the diabetic foot. Lancet. 2005;366(9498):1736-1743.
11.
FrykbergRG.Diabetic foot ulcers: pathogenesis and management. Am Fam Physician. 2002;66(9):1655-1662.
12.
GalkowskaHWojewodzkaUOlszewskiWL.Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers. Wound Repair Regen. 2006;14(5):558-565.
13.
GlassGEMurphyGFEsmaeiliALaiLMNanchahalJ.Systematic review of molecular mechanism of action of negative-pressure wound therapy. Br J Surg. 2014;101(13):1627-1636.
14.
HuangCLeavittTBayerLROrgillDP.Effect of negative pressure wound therapy on wound healing. Curr Probl Surg. 2014;51(7):301-331.
15.
JanisJEHarrisonB.Wound healing: part I. Basic science. Plast Reconstr Surg. 2014;133(2):199e-207e.
16.
JudeEBBlakytnyRBulmerJBoultonAJFergusonMW.Transforming growth factor-beta 1, 2, 3 and receptor type I and II in diabetic foot ulcers. Diabet Med. 2002;19(6):440-447.
17.
KilpadiDVBowerCEReadeCC. Effect of vacuum assisted closure therapy on early systemic cytokine levels in a swine model. Wound Repair Regen. 2006;14(2):210-215.
18.
LuFOgawaRNguyenDT. Microdeformation of three-dimensional cultured fibroblasts induces gene expression and morphological changes. Ann Plast Surg. 2011;66(3):296-300.
MargadantCSonnenbergA.Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep. 2010;11(2):97-105.
21.
McNultyAKSchmidtMFeeleyTVillanuevaPKieswetterK.Effects of negative pressure wound therapy on cellular energetics in fibroblasts grown in a provisional wound (fibrin) matrix. Wound Repair Regen. 2009;17(2):192-199.
22.
MouesCMVosMCvan den BemdGJStijnenTHoviusSE.Bacterial load in relation to vacuum-assisted closure wound therapy: a prospective randomized trial. Wound Repair Regen. 2004;12(1):11-17.
23.
OrgillDPBayerLR.Update on negative-pressure wound therapy. Plast Reconstr Surg. 2011;127(suppl 1):105S-115S.
24.
OrgillDPBayerLR.Negative pressure wound therapy: past, present and future. Int Wound J. 2013;10(suppl 1):15-19.
25.
PankovRYamadaKM.Fibronectin at a glance. J Cell Sci. 2002;115(pt 20):3861-3863.
26.
PintoATuttolomondoADi RaimondoD. Cardiovascular risk profile and morbidity in subjects affected by type 2 diabetes mellitus with and without diabetic foot. Metabolism. 2008;57(5):676-682.
27.
RafehiHEl-OstaAKaragiannisTC.Epigenetic mechanisms in the pathogenesis of diabetic foot ulcers. J Diabetes Complications. 2012;26(6):554-561.
28.
RaghowRPostlethwaiteAEKeski-OjaJMosesHLKangAH.Transforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest. 1987;79(4):1285-1288.
29.
ReinkeJMSorgH.Wound repair and regeneration. Eur Surg Res. 2012;49(1):35-43.
30.
SchintlerMV.Negative pressure therapy: theory and practice. Diabetes Metab Res Rev. 2012;28(suppl 1):72-77.
31.
SinghPCarraherCSchwarzbauerJE.Assembly of fibronectin extracellular matrix. Annu Rev Cell Dev Biol. 2010;26:397-419.
32.
StanleyCMWangYPalS. Fibronectin fragmentation is a feature of periodontal disease sites and diabetic foot and leg wounds and modifies cell behavior. J Periodontol. 2008;79(5):861-875.
33.
StoffelsJMZhaoCBaronW.Fibronectin in tissue regeneration: timely disassembly of the scaffold is necessary to complete the build. Cell Mol Life Sci. 2013;70(22):4243-4253.
34.
SuhHLeeAYParkEJHongJP.Negative pressure wound therapy on closed surgical wounds with dead space: animal study using a swine model. Ann Plast Surg. 2016;76(6):717-722.
35.
TingKMRothauptDMcCormickTS. Overexpression of the oncofetal Fn variant containing the EDA splice-in segment in the dermal-epidermal junction of psoriatic uninvolved skin. J Invest Dermatol. 2000;114(4):706-711.
36.
van der StraatenHMCanninga-van DijkMRVerdonckLF. Extra-domain-A fibronectin: a new marker of fibrosis in cutaneous graft-versus-host disease. J Invest Dermatol. 2004;123(6):1057-1062.
37.
WackenforsASjogrenJGustafssonR. Effects of vacuum-assisted closure therapy on inguinal wound edge microvascular blood flow. Wound Repair Regen. 2004;12(6):600-606.
38.
WernerSGroseR.Regulation of wound healing by growth factors and cytokines. Physiol Rev. 2003;83(3):835-870.
39.
WhitingDRGuariguataLWeilCShawJ.IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311-321.
40.
WrobelJSMayfieldJAReiberGE.Geographic variation of lower-extremity major amputation in individuals with and without diabetes in the Medicare population. Diabetes Care. 2001;24(5):860-864.
41.
WukichDKHobizalKBBrooksMM.Severity of diabetic foot infection and rate of limb salvage. Foot Ankle Int. 2013;34(3):351-358.
42.
WysockiAB.Wound fluids and the pathogenesis of chronic wounds. J Wound Ostomy Continence Nurs. 1996;23(6):283-290.
43.
WysockiABGrinnellF.Fibronectin profiles in normal and chronic wound fluid. Lab Invest. 1990;63(6):825-831.
44.
YangSLHanRLiuYHuLYLiXLZhuLY. Negative pressure wound therapy is associated with up-regulation of bFGF and ERK1/2 in human diabetic foot wounds. Wound Repair Regen. 2014; 22(4): 548-554.
45.
ZhangJHuZCChenD. Effectiveness and safety of negative-pressure wound therapy for diabetic foot ulcers: a meta-analysis. Plast Reconstr Surg. 2014;134(1):141-151.
